Sioud, Mouldy.
Mouldy Sioud researcher
Sioud, Mouldy, 1958-....
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
VIAF ID: 59188168 (Personal)
Permalink: http://viaf.org/viaf/59188168
Preferred Forms
-
100 0 _
‡a
Mouldy Sioud
‡c
researcher
-
200 _ |
‡a
Sioud
‡b
Mouldy
‡f
1958-....
-
100 1 _ ‡a Sioud, Mouldy
-
100 1 _ ‡a Sioud, Mouldy
-
100 1 _
‡a
Sioud, Mouldy
-
100 1 _
‡a
Sioud, Mouldy
-
100 1 _ ‡a Sioud, Mouldy
-
100 1 _
‡a
Sioud, Mouldy
-
100 1 _ ‡a Sioud, Mouldy
-
100 1 _
‡a
Sioud, Mouldy
‡d
1958-...
-
100 1 _
‡a
Sioud, Mouldy,
‡d
1958-....
-
100 1 _ ‡a Sioud, Mouldy.
4xx's: Alternate Name Forms (1)
5xx's: Related Names (1)
Works
| Title | Sources |
|---|---|
| Etude des mécanismes moléculaires d'action des inhibiteurs des ADN topoisomérases II chez les archaebactéries halophiles |
|
| Gene-array analysis of glioma cells after treatment with an anti-PKCalpha siRNA: a general protocol |
|
| Gene silencing in mammalian cells by preformed small RNA duplexes |
|
| Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens. |
|
| Generation of new peptide-Fc fusion proteins that mediate antibody-dependent cellular cytotoxicity against different types of cancer cells |
|
| Harnessing the Antiviral-Type Responses Induced by Immunostimulatory siRNAs for Cancer Immunotherapy |
|
| How does autoimmunity cause tumor regression? A potential mechanism involving cross-reaction through epitope mimicry |
|
| Identification of a novel centrosome/microtubule-associated coiled-coil protein involved in cell-cycle progression and spindle organization |
|
| Identification of genes differentially expressed in breast cancer cell line SKBR3: potential identification of new prognostic biomarkers |
|
| Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses |
|
| Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands |
|
| Improving Dendritic Cell Cancer Vaccine Potency Using RNA Interference |
|
| Increased miR-21 expression during human monocyte differentiation into DCs |
|
| Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization |
|
| Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model |
|
| Inhibition of gene expression by nucleic acid enzymes in rodent models of human disease |
|
| Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts. |
|
| Innate sensing of self and non-self RNAs by Toll-like receptors |
|
| Lamin A/C cleavage by caspase-6 activation is crucial for apoptotic induction by photodynamic therapy with hexaminolevulinate in human B-cell lymphoma cells |
|
| Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. |
|
| Microbial sensing by hematopoietic stem and progenitor cells: Vigilance against infections and immune education of myeloid cells |
|
| Modified 2'-ribose small RNAs function as Toll-like receptor-7/8 antagonists |
|
| Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy |
|
| Modulation of dendritic cell maturation and function by siRNA-bearing 5'-triphosphate |
|
| Monitoring B cell response to immunoselected phage-displayed peptides by microarrays |
|
| Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma. |
|
| Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted? |
|
| NOD2/CARD15 on bone marrow CD34+ hematopoietic cells mediates induction of cytokines and cell differentiation |
|
| Overcoming self-tolerance to tumour cells |
|
| Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs |
|
| Phage Display Libraries: From Binders to Targeted Drug Delivery and Human Therapeutics |
|
| Potential design rules and enzymatic synthesis of siRNAs |
|
| Profiling microRNA expression using sensitive cDNA probes and filter arrays |
|
| Profiling of miRNA expression and prediction of target genes |
|
| Promises and challenges in developing RNAi as a research tool and therapy |
|
| Protein arrays: a versatile toolbox for target identification and monitoring of patient immune responses |
|
| Recent advances in hematopoietic stem cell transplantation and perspectives of RNAi applications |
|
| Recombinant Lactobacillus plantarum induces immune responses to cancer testis antigen NY-ESO-1 and maturation of dendritic cells |
|
| Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy |
|
| Ribozyme- and siRNA-mediated mRNA degradation: a general introduction |
|
| Ribozymes and siRNA protocols |
|
| Ribozymes, DNAzymes and small interfering RNAs as therapeutics |
|
| RNA and CRISPR Interferences: Past, Present, and Future Perspectives |
|
| RNA interference below the immune radar |
|
| RNA interference : challenges and therapeutic opportunities |
|
| RNA therapeutics : function, design, and delivery |
|
| Selection of peptides for specific delivery of oligonucleotides into cancer cells |
|
| Selective Killing of Activated T Cells by 5-Aminolevulinic Acid Mediated Photodynamic Effect: Potential Improvement of Extracorporeal Photopheresis |
|
| Selective targeting of cancer cells using synthetic peptides |
|
| Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients |
|
| Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses |
|
| siRNA and miRNA gene silencing : from bench to bedside |
|
| siRNA delivery in vivo |
|
| Strategies for siRNA navigation to desired cells |
|
| Strategies for the design of random siRNA libraries and the selection of anti-GFP siRNAs |
|
| Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma |
|
| Suppression of immunostimulatory siRNA-driven innate immune activation by 2'-modified RNAs. |
|
| Systematic search for natural antisense transcripts in eukaryotes (review) |
|
| Systemic delivery of synthetic siRNAs |
|
| T cell cross-reactivity may explain the large variation in how patients respond to checkpoint inhibitors. |
|
| Target discovery and validation reviews and protocols |
|
| Target validation using RNA interference in solid tumors. |
|
| Targeted delivery of antisense oligonucleotides and siRNAs into mammalian cells |
|
| Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides |
|
| Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth |
|
| TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response |
|
| Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. |
|
| Transcriptional targeting of small interfering RNAs into cancer cells |
|
| Treatment options and individualized medicine |
|
| Tyrosine kinase receptor-ras-ERK signal transduction pathway as therapeutic tarfet in cancer |
|
| What are the key targeted delivery technologies of siRNA now? |
|
